A Framework for Interactive Problem Solving Based on Interactive Query Revision

M. Ohki,A. Takeuchi,K. Furukawa

DOI: https://doi.org/10.1007/3-540-18024-9_29

1986-06-23

Abstract:

What problem does this paper attempt to address?

[Advances in Newborn Screening and Immune System Reconstitution of Severe Combined Immunodeficiency].

Shumin Huang,Zhengyan Zhao

DOI: https://doi.org/10.3785/j.issn.1008-9292.2019.08.01

2019-01-01

Abstract:Severe combined immunodeficiency disease (SCID) is a group of rare congenital diseases characterized by severe deficiencies in T lymphocyte counts and/or function. The recurrent, persistent and severe infections are its clinical manifestations. Neonatal screening and immune system reconstruction would improve the prognosis of SCID children. Newborn screening programs based on T-cell receptor excision circles (TRECs) quantitative detection have been carried out in clinical practice, however, the methods still have some limitations. Other new methods such as mass spectrometry and T lymphocyte-specific biomarker assays are still under investigation. Hematopoietic stem cell transplantation and gene therapy are the two main methods for reconstructing immune function in SCID children. Through improving the success rate of transplantation and the long-term safety and stability of viral vectors, some achievements have been made by many centers already. However, large-scale prospective studies are needed for evaluation of the long-term efficacy. In this article, the recent progress in newborn screening and immune reconstitution of SCID is reviewed.
Family members' informal roles in end-of-life decision making in adult intensive care units.

Jill Quinn,M. Schmitt,J. Baggs,S. Norton,M. Dombeck,Craig R. Sellers

DOI: https://doi.org/10.4037/ajcc2012520

American Journal of Critical Care

Abstract:BACKGROUND To support the process of effective family decision making, it is important to recognize and understand informal roles that various family members may play in the end-of-life decision-making process. OBJECTIVE To describe some informal roles consistently enacted by family members involved in the process of end-of-life decision making in intensive care units. METHODS Ethnographic study. Data were collected via participant observation with field notes and semistructured interviews on 4 intensive care units in an academic health center in the mid-Atlantic United States from 2001 to 2004. The units studied were a medical, a surgical, a burn and trauma, and a cardiovascular intensive care unit. PARTICIPANTS Health care clinicians, patients, and family members. RESULTS Informal roles for family members consistently observed were primary caregiver, primary decision maker, family spokesperson, out-of-towner, patient's wishes expert, protector, vulnerable member, and health care expert. The identified informal roles were part of families' decision-making processes, and each role was part of a potentially complicated family dynamic for end-of-life decision making within the family system and between the family and health care domains. CONCLUSIONS These informal roles reflect the diverse responses to demands for family decision making in what is usually a novel and stressful situation. Identification and description of these informal roles of family members can help clinicians recognize and understand the functions of these roles in families' decision making at the end of life and guide development of strategies to support and facilitate increased effectiveness of family discussions and decision-making processes.
Reducing Mortality and Morbidity in Children with Severe Combined Immunodeficiency in Switzerland: the Role of Newborn Screening

Maarja Soomann,Seraina Prader,Aline Pinto Monteiro,Ulrike Zeilhofer,Mathias Hauri-Hohl,Tayfun Güngör,Jana Pachlopnik Schmid,Johannes Trück,Matthias Felber

DOI: https://doi.org/10.1007/s10875-023-01640-2

IF: 8.542

2024-01-03

Journal of Clinical Immunology

Abstract:Newborn screening (NBS) for severe combined immunodeficiency (SCID) has been introduced in various countries with the aim of reducing morbidity and mortality. However, studies analyzing outcomes before and after the implementation of NBS programs remain limited. This study sought to compare the outcomes of SCID patients identified through Switzerland's national SCID NBS program, introduced in January 2019, with those of a historical cohort diagnosed between 2007 and 2019. The study included seven patients (32%) identified through NBS, and 15 (68%) born before NBS implementation and diagnosed based on clinical signs. Children in the NBS group were younger at diagnosis (median age 9 days vs 9 months, P = .002) and at hematopoietic stem cell transplantation (HSCT, median age 5 months vs 11 months, P = .003) compared to the clinical group. The NBS group had a lower incidence of infections before HSCT (29% vs 93%, P = .004). Although not statistically significant, the overall survival rate on last follow-up was higher in the NBS group (86% vs 67%, P = .62). Importantly, patients with active infections undergoing HSCT had a significantly lower overall survival probability compared to those without ( P = .01). In conclusion, the introduction of NBS in Switzerland has led to earlier and often asymptomatic diagnosis of affected children, enabling timely intervention, infection prevention, and prompt treatment. These factors have contributed to higher survival rates in the NBS group. These findings underscore the critical importance of NBS for SCID, offering potential life-saving benefits through early detection and intervention.

immunology
A Modular Genetic Approach to Newborn Screening from Spinal Muscular Atrophy to Sickle Cell Disease—Results from Six Years of Genetic Newborn Screening

Jessica Bzdok,Ludwig Czibere,Siegfried Burggraf,Natalie Pauly,Esther M. Maier,Wulf Röschinger,Marc Becker,Jürgen Durner

DOI: https://doi.org/10.3390/genes15111467

IF: 4.141

2024-11-16

Genes

Abstract:Background/Objectives: Genetic newborn screening (NBS) has already entered the phase of common practice in many countries. In Germany, spinal muscular atrophy (SMA), severe combined immunodeficiency (SCID) and sickle cell disease (SCD) are currently a mandatory part of NBS. Here, we describe the experience of six years of genetic NBS including the prevalence of those three diseases in Germany. Methods: Samples and nucleic acids were extracted from dried blood spot cards, commonly used for NBS. A qPCR assay was used to detect disease-causing variants for SMA and SCD, and the detection of T-cell receptor excision circles (TRECs) was performed for SCID screening. Results: The results of the NBS of over 1 million newborns for SMA, approximately 770,000 for SCID and over 410,000 for SCD are discussed in detail. In these newborns, we have identified 121 cases of SMA, 15 cases of SCID and syndrome-based immunodeficiencies and 77 cases of SCD or β-thalassemia. Conclusions: The flexibility of multiplex qPCR is assessed as an effective tool for incorporating different molecular genetic markers for screening. The processing of dried blood spot (DBS) filter cards for molecular genetic assays and the assays are described in detail; turn-around times and cost estimations are included to give an insight into the processes and discuss further options for optimization. The identified cases are in the range expected for the total number of screened newborns, but present a more exact view on the actual prevalences for Germany.

genetics & heredity
[Inapparent forms of edema in infectious hepatitis].

R. Cachera,F. Darnis

1951-06-01

Abstract:
Clinical and economic aspects of newborn screening for severe combined immunodeficiency: DEPISTREC study results

Caroline Thomas,Isabelle Durand-Zaleski,Jérôme Frenkiel,Sophie Mirallié,Alexandra Léger,David Cheillan,Capucine Picard,Nizar Mahlaoui,Valéry-Pierre Riche,Michel Roussey,Véronique Sébille,Hasina Rabetrano,Cécile Dert,Alain Fischer,Marie Audrain

DOI: https://doi.org/10.1016/j.clim.2019.03.012

Abstract:Purpose: Severe combined immunodeficiency (SCID) refers to a group of genetic disorders characterized by greatly compromised cellular and humoral immunity. Children with SCID are asymptomatic at birth, but they die from infections within the first months of life if not treated. Quantification of T-cell receptor excision circles is an extremely sensitive screening method for detecting newborns who may have SCID.The goal of the DEPISTREC study was to evaluate the feasibility of nationwide newborn screening for severe T-cell lymphopenia in France as well as its economic and clinical utility. Methods: The test universally used for neonatal screening for SCID was the quantification of TRECs on Guthrie cards. We compared a group of 190,517 babies from 48 maternities across the country who underwent newborn SCID screening with a control group of 1.4 million babies out of whom 28 were diagnosed with SCID without such screening during the course of the study. Results: Within the screening group, 62 babies were found to be lymphopenic, including three with SCID. The cost of screening ranged from 4.7€ to €8.15 per newborn. The average 18-month cost was €257,574 vs €204,697 in the control group. Conclusions: In this large-scale study, we demonstrate that routine SCID screening is feasible and effective. This screening offers the additional benefit of aiding in the diagnosis of non-SCID lymphopenia. Economic evaluation allowed us to calculate the cost per test. Newborn screening may also prevent death by SCID before any curative treatment can be administered. The difference in cost between screened and control children could not be ascertained because of the very low numbers and death of one of the children tested.
AT1 receptors mediate chronic central nervous system AII hypertension in rats fed high sodium chloride diet from weaning.

A. Camara,J. Osborn

DOI: https://doi.org/10.1016/S0165-1838(98)00080-0

1998-08-06

Journal of the Autonomic Nervous System

Abstract:
Severe combined immunodeficiency with a homozygous c.464T>C (p.Leu155Pro) mutation in the RAG2 gene in a country without neonatal screening: Report of two clinical cases

Zurisadai Raquel García Osorno,Augusto Ignacio Siegert Olivares,Paola Alejandra Cisneros Conklin,Ibeth Judith Reyes Montante,María Andrea Murillo Gallo

DOI: https://doi.org/10.53022/oarjbp.2023.9.1.0046

2023-10-30

Open Access Research Journal of Biology and Pharmacy

Abstract:Introduction: Severe combined immunodeficiency (SCID) is a disorder belonging to the broad spectrum of inborn errors of immunity (IEI), characterized by a predisposition to develop recurrent, severe, difficult-to-treat opportunistic infections. This disorder is associated with abnormalities in genes of the adaptive immune system and should be suspected in patients with infections during the first months of life, mainly due to fungal pathogens and intracellular agents. Case Presentation: Two cases of SCID diagnosed at the General Hospital with Specialties "Juan María de Salvatierra” in Baja California Sur (BCS), México in 2022 are described. The first patient presented persistent candidiasis stomatitis with no response to oral treatment. The second patient presented mycotic dermatitis and oropharyngeal candidiasis compatible with Candida albicans and multiple episodes of multi-treated airway infection with partial remission. The diagnosis was completed with a genetic panel that showed a mutation in RAG2 homozygous variant c.464T>C (p.Leu155Pro) in both patients. Conclusions: SCID should be considered in patients with recurrent and difficult-to-treat infectious diseases in the first months of life. For its timely detection, implementing neonatal screening quantifying of T-cell receptor excision circles (TRECs) is recommended. This method is not available in Mexico, so it has been relevant to have physicians trained in the timely clinical identification of the disease. Thanks to the prompt referral of both patients to our hospital, we could treat the comorbidities associated with SCID, provide a specific molecular diagnosis, and transfer the patients to a hospital specialized in bone marrow transplantation for definitive treatment.
Severe combined immunodeficiency diagnosis and genetic defects

Carolina Sanchez Aranda,Mariana Pimentel Gouveia‐Pereira,Celso Jose Mendanha da Silva,Maria Candida Faria Varanda Rizzo,Edson Ishizuka,Edgar Borges de Oliveira,Antonio Condino‐Neto

DOI: https://doi.org/10.1111/imr.13310

2024-01-31

Immunological Reviews

Abstract:Summary Severe combined immunodeficiency (SCID) is a rare and life‐threatening genetic disorder that severely impairs the immune system's ability to defend the body against infections. Often referred to as the "bubble boy" disease, SCID gained widespread recognition due to the case of David Vetter, a young boy who lived in a sterile plastic bubble to protect him from germs. SCID is typically present at birth, and it results from genetic mutations that affect the development and function of immune cells, particularly T cells and B cells. These immune cells are essential for identifying and fighting off infections caused by viruses, bacteria, and fungi. In SCID patients, the immune system is virtually non‐existent, leaving them highly susceptible to recurrent, severe infections. There are several forms of SCID, with varying degrees of severity, but all share common features. Newborns with SCID often exhibit symptoms such as chronic diarrhea, thrush, skin rashes, and persistent infections that do not respond to standard treatments. Without prompt diagnosis and intervention, SCID can lead to life‐threatening complications and a high risk of mortality. There are over 20 possible affected genes. Treatment options for SCID primarily involve immune reconstitution, with the most well‐known approach being hematopoietic stem cell transplantation (HSCT). Alternatively, gene therapy is also available for some forms of SCID. Once treated successfully, SCID patients can lead relatively normal lives, but they may still require vigilant infection control measures and lifelong medical follow‐up to manage potential complications. In conclusion, severe combined immunodeficiency is a rare but life‐threatening genetic disorder that severely compromises the immune system's function, rendering affected individuals highly vulnerable to infections. Early diagnosis and appropriate treatment are fundamental. With this respect, newborn screening is progressively and dramatically improving the prognosis of SCID.

immunology
A Multicenter Prospective Study of Next-Generation Sequencing-Based Newborn Screening for Monogenic Genetic Diseases in China

Ru-Lai Yang,Gu-Ling Qian,Ding-Wen Wu,Jing-Kun Miao,Xue Yang,Ben-Qing Wu,Ya-Qiong Yan,Hai-Bo Li,Xin-Mei Mao,Jun He,Huan Shen,Hui Zou,Shu-Yuan Xue,Xiao-Ze Li,Ting-Ting Niu,Rui Xiao,Zheng-Yan Zhao

DOI: https://doi.org/10.1007/s12519-022-00670-x

2023-01-01

Abstract:BackgroundNewborn screening (NBS) is an important and successful public health program that helps improve the long-term clinical outcomes of newborns by providing early diagnosis and treatment of certain inborn diseases. The development of next-generation sequencing (NGS) technology provides new opportunities to expand current newborn screening methodologies.MethodsWe designed a a newborn genetic screening (NBGS) panel targeting 135 genes associated with 75 inborn disorders by multiplex PCR combined with NGS. With this panel, a large-scale, multicenter, prospective multidisease analysis was conducted on dried blood spot (DBS) profiles from 21,442 neonates nationwide.ResultsWe presented the positive detection rate and carrier frequency of diseases and related variants in different regions; and 168 (0.78%) positive cases were detected. Glucose-6-Phosphate Dehydrogenase deficiency (G6PDD) and phenylketonuria (PKU) had higher prevalence rates, which were significantly different in different regions. The positive detection of G6PD variants was quite common in south China, whereas PAH variants were most commonly identified in north China. In addition, NBGS identified 3 cases with DUOX2 variants and one with SLC25A13 variants, which were normal in conventional NBS, but were confirmed later as abnormal in repeated biochemical testing after recall. Eighty percent of high-frequency gene carriers and 60% of high-frequency variant carriers had obvious regional differences. On the premise that there was no significant difference in birth weight and gestational age, the biochemical indicators of SLC22A5 c.1400C > G and ACADSB c.1165A > G carriers were significantly different from those of non-carriers.ConclusionsWe demonstrated that NBGS is an effective strategy to identify neonates affected with treatable diseases as a supplement to current NBS methods. Our data also showed that the prevalence of diseases has significant regional characteristics, which provides a theoretical basis for screening diseases in different regions.
Application of a Next-Generation Sequencing (NGS) Panel in Newborn Screening Efficiently Identifies Inborn Disorders of Neonates

Huang Xinwen,Wu Dingwen,Zhu Lin,Wang Wenjun,Yang Rulai,Yang Jianbin,He Qunyan,Zhu Bingquan,You Ying,Xiao Rui,Zhao Zhengyan

DOI: https://doi.org/10.1186/s13023-022-02231-x

2022-01-01

Orphanet Journal of Rare Diseases

Abstract:BACKGROUND:Newborn screening (NBS) has been implemented for neonatal inborn disorders using various technology platforms, but false-positive and false-negative results are still common. In addition, target diseases of NBS are limited by suitable biomarkers. Here we sought to assess the feasibility of further improving the screening using next-generation sequencing technology.METHODS:We designed a newborn genetic sequencing (NBGS) panel based on multiplex PCR and next generation sequencing to analyze 134 genes of 74 inborn disorders, that were validated in 287 samples with previously known mutations. A retrospective cohort of 4986 newborns was analyzed and compared with the biochemical results to evaluate the performance of this panel.RESULTS:The accuracy of the panel was 99.65% with all samples, and 154 mutations from 287 samples were 100% detected. In 4986 newborns, a total of 113 newborns were detected with biallelic or hemizygous mutations, of which 36 newborns were positive for the same disorder by both NBGS and conventional NBS (C-NBS) and 77 individuals were NBGS positive/C-NBS negative. Importantly, 4 of the 77 newborns were diagnosed currently including 1 newborn with methylmalonic acidemia, 1 newborn with primary systemic carnitine deficiency and 2 newborns with Wilson's disease. A total of 1326 newborns were found to be carriers with an overall carrier rate of 26.6%.CONCLUSION:Analysis based on next generation sequencing could effectively identify neonates affected with more congenital disorders. Combined with C-NBS, this approach may improve the early and accurate identification of neonates with inborn disorders. Our study lays the foundation for prospective studies and for implementing NGS-based analysis in NBS.
Importance of the route of administration of ccl 4 in the protective effect of promethazine.

D. Nadeau,C. Marchand

DOI: https://doi.org/10.1016/0006-2952(73)90246-3

IF: 6.1

1973-05-15

Biochemical Pharmacology

Abstract:
A novel pathogenic mutation on Interleukin-7 receptor leading to severe combined immunodeficiency identified with newborn screening and whole exome sequencing

Cheng-Yu Liao,Hui-Wen Yu,Chao-Neng Cheng,Jiann-Shiuh Chen,Ching-Wei Lin,Peng-Chieh Chen,Chi-Chang Shieh

DOI: https://doi.org/10.1016/j.jmii.2018.02.003

Abstract:Background: Patients with severe combined immunodeficiency (SCID), which is caused by genetic defects in immune-related genes involved in the development or activation of the adaptive immune system, often died in infancy due to severe infections before definite molecular diagnosis could be made. Although recent improvement in early diagnosis has been achieved by newborn screening, the genetic basis of many of the patients is still unknown. Methods: Here we performed whole exome sequencing (WES) to investigate the underlying genetic causes of SCID in a proband identified with newborn screening. Inheritance of the mutation was confirmed with targeted sequencing of the parents. Homozygosity mapping from the WES was used to investigate the consanguinity of the parents. Immunoblotting was used to confirm the loss of expression of the mutant protein. Results: A novel homozygous frameshift mutation of IL7R was identified through WES. Both parents are carriers for this 1-bp deletion. HLA typing and exome-wide homozygous stretch mapping suggested that the parents are consanguineous. Immunoblotting showed no expression of IL7Rα isoform in the whole blood sample of the proband. The proband received peripheral blood stem cell transplantation and her general condition became stable. Our results suggest that IL7R is essential for T cell development but dispensable for the development of certain human NK cells B cells and suggest that WES can be a useful tool for precise genetic diagnosis of SCID following newborn screening in the index patient without the need to screen other members of the whole family.
Paving the way in implementation of SCID newborn screening in developing nations: feasibility study and strategies to move forward in Malaysia

Gaayathri Kumarasamy,Khayrin Khairiz,Wai Leng Chang,Thin Thin Aye,Adli Ali

DOI: https://doi.org/10.3389/fimmu.2024.1400247

IF: 7.3

2024-06-25

Frontiers in Immunology

Abstract:Early diagnosis and effective management of Primary immunodeficiency diseases (PIDs), particularly severe combined immunodeficiency (SCID), play a crucial role in minimizing associated morbidities and mortality. Newborn screening (NBS) serves as a valuable tool in facilitating these efforts. Timely detection and diagnosis are essential for swiftly implementing isolation measures and ensuring prompt referral for definitive treatment, such as allogeneic hematopoietic stem cell transplantation. The utilization of comprehensive protocols and screening assays, including T cell receptor excision circles (TREC) and kappa-deleting recombination excision circles (KREC), is essential in facilitating early diagnosis of SCID and other PIDs, but their successful application requires clinical expertise and proper implementation strategy. Unfortunately, a notable challenge arises from insufficient funding for the treatment of PIDs. To address these issues, a collaborative approach is imperative, involving advancements in technology, a well-functioning healthcare system, and active engagement from stakeholders. The integration of these elements is essential for overcoming the existing challenges in NBS for PIDs. By fostering synergy between technology providers, healthcare professionals, and governmental stakeholders, we can enhance the efficiency and effectiveness of early diagnosis and intervention, ultimately improving outcomes for individuals with PIDs.

immunology
Target Diseases for Neonatal Screening in Germany

Ute Spiekerkoetter,Heiko Krude

DOI: https://doi.org/10.3238/arztebl.m2022.0075

2022-04-29

Abstract:Background: Neonatal screening in Germany currently comprises 19 congenital diseases, 13 of which are metabolic diseases. Approximately one in 1300 newborns suffers from one of these target diseases. Early diagnosis and treatment enable the affected children to undergo better development and even, in many cases, to have a normal life. Methods: This review is based on pertinent publications retrieved by a selective search in the PubMed and Embase databases. Results: Positive screening findings are confirmed in approximately one out of five newborns. The prompt evaluation of suspected diagnoses is essential, as treatment for some of these diseases must be initiated immediately after birth to prevent longterm sequelae. The most commonly identified diseases are primary hypothyroidism (1:3338), phenylketonuria/hyperphenylalaninemia (1 : 5262), cystic fibrosis (1 : 5400), and medium-chain acyl-CoA dehydrogenase deficiency (1 : 10 086). Patient numbers are rising as new variants of the target diseases are being identified, and treatments must be adapted to their heterogeneous manifestations. Precise diagnosis and the planning of treatment, which is generally lifelong, are best carried out in a specialized center. Conclusion: Improved diagnosis and treatment now prolong the lives of many patients with congenital diseases. The provision of appropriate long-term treatment extending into adulthood will be a central structural task for screening medicine in the future.
A report of two cases of severe X-linked combined immunodeficiency in one family and literature review

WANG Wen-jie,CHEN Guan-rong,WANG Xiao-chuan,WANG Ying,LIU Yu-long,SHEN Shui-xian,ZHANG Ling-en

DOI: https://doi.org/10.3969/j.issn.1673-5501.2007.05.004

2007-01-01

Abstract:Objective To investigate the clinical manifestations,diagnostic methods and treatment of severe combined immunodeficiency (SCID).Methods The patient presented at the age of 2 months with frequent pneumonia and a history of chronic oral candidiasis even when treated adequately with antibiotics or anti-fungi agents. Flow cytometric analysis was used to assess T cells. Cell surface markers of peripheral blood cells were determined by immunofluorescent staining and flow cytometry with antibodies purchased from BD company. IL-2R gene was analyzed by PCR and sequence was performed for the patient and partial maternal family members. Clinical documented information of the patient and his uncle died during early life was reviewed. His peripheral blood mononuclear cells were incubated at 37 ℃ in complete culture medium RPMI-1640. Cells were incubated in round bottom tissue culture plates with PHA for 72 h, and 18-20 hours before termination of the culture, thymidine was added to each well. The cells were then harvested and samples were counted in a liquid scintillation counter.Results The patient had a very low T-cell number. Initial investigations revealed a total white blood cell count of 2.8×109·L-1 [reference range, (5.4-9.4)×109·L-1] with a lymphocyte count of 1.9×109·L-1 [reference range, (2.8-5.7)×109·L-1], the results of flow cytometric analysis showed CD3+0, CD4+0, CD8+0, CD19+ 95%, CD16+CD56+ 4%. Sequencing of his IL-2RG revealed a G deletion at 849 in exon 6, the consequence showed frameshift start form cysteine 278, "TGA" stop codon created at position 293. His mother was confirmed to be a carrier, she didn't seem to be a simple heterozygote,but maybe mosaic mutation with mixed population in leucocytes. His uncle died of severe incurable infection and without mononuclear proliferation to PHA stimulation. He presented hyperpyrexia, rash and splenohepatomegalia after recieving transfusion of untreated fresh blood. Considering his family history, his uncle's clinical manifestation was high likely due to graft versus host disease. IL2R gene analysis was also done for his newborn sister after family survey.His sister was confirmed to be the same mutation as her mother.Conclusions Genetic diagnosis was made for one X-SCID patient caused by IL-2RG. And after family survey, his mother and sister were confirmed to be carriers, maybe mosaic mutation with mixed population in leucocytes. Infant with severe infection even after treated with adequate standard treatment, should be considered the possibility of suffering SCID and immune function evaluation should be taken. As the underlying severe disorders, the living vaccine and untreated blood products transfusion must be restrained. Early immune reconstitution including bone marrow or stem cell transplantation offers the best chance of long-term survival. Medical workers should pay more attention to immunodeficiency.
Absence of short-loop autoregulation of prolactin during late pregnancy in the rat

D. Grattan,R. Averill

DOI: https://doi.org/10.1016/0361-9230(94)00216-N

IF: 3.715

1995-12-31

Brain Research Bulletin

Abstract:
Mass is more: The conceiving of (un)countability and its encoding into language in 5-year-old-children

Chiara Zanini,S. Benavides-Varela,Riccardina Lorusso,Francesca Franzon

DOI: https://doi.org/10.3758/s13423-016-1187-2

2017-08-01

Psychonomic Bulletin & Review

Abstract:
A Large Cohort of RAG1/2-Deficient SCID Patients—Clinical, Immunological, and Prognostic Analysis

Noa Greenberg-Kushnir,Yu Nee Lee,Amos J. Simon,Atar Lev,Nufar Marcus,Omar Abuzaitoun,Raz Somech,Tali Stauber

DOI: https://doi.org/10.1007/s10875-019-00717-1

IF: 8.542

2019-12-14

Journal of Clinical Immunology

Abstract:<h3 class="Heading">Introduction</h3><p class="Para">Severe combined immunodeficiency (SCID) is a fatal disorder resulting from various genetic defects. In the Middle East, where consanguineous marriage is prevalent, autosomal recessive mutations in recombination-activating genes (RAG) are a leading cause of SCID. We present a large cohort of SCID patients due to RAG1 or RAG2 mutations.</p><h3 class="Heading">Methods</h3><p class="Para">Twenty-six patients with RAG1 or RAG2 deficiency, diagnosed at Sheba Medical Center, were retrospectively investigated. Clinical presentation, immunologic phenotype, genetic analysis, treatment, and outcome were analyzed.</p><h3 class="Heading">Results</h3><p class="Para">Majority of patients were referred from the Palestinian Authority. Most patients were males of Muslim Arab descent, 77% were born to consanguineous parents, and 65% had family history of immunodeficiency. Nearly all patients suffered from various infections before turning 2 months old, eight patients (31%) presented with Omenn and Omenn-like syndrome, and three patients (11%) had maternal engraftment. Notably, seven patients (27%) suffered from vaccine-derived infections, including a rare case of measles encephalitis. Nineteen patients underwent hematopoietic stem cell transplantation (HSCT) at a median age of 6 months, with a successful outcome for 72% of them. Genetic analysis revealed 11 different mutations (7 RAG2, 4 RAG1), two of them novel.</p><h3 class="Heading">Conclusions</h3><p class="Para">Consanguineous marriages account for a genetic "founder effect." SCID is a pediatric emergency that dictates immediate precautions and curative treatment with HSCT. Due to lack of newborn screening for SCID within the Palestinian population, most patients in this cohort were diagnosed upon clinical symptoms, which led to a delayed diagnosis, harmful administration of contra-indicated live vaccines, delay in HSCT, and poor outcome.</p>

immunology
Survival After Hematopoietic Stem Cell Transplantation in Severe Combined Immunodeficiency (SCID): A Worldwide Review of the Prognostic Variables

Gabriela Assunção Goebel,Cíntia Silva de Assis,Luciana Araújo Oliveira Cunha,Fernanda Gontijo Minafra,Jorge Andrade Pinto

DOI: https://doi.org/10.1007/s12016-024-08993-5

2024-05-02

Clinical Reviews in Allergy & Immunology

Abstract:This study aims to perform an extensive review of the literature that evaluates various factors that affect the survival rates of patients with severe combined immunodeficiency (SCID) after hematopoietic stem cell transplantation (HSCT) in developed and developing countries. An extensive search of the literature was made in four different databases (PubMed, Embase, Scopus, and Web of Science). The search was carried out in December 2022 and updated in July 2023, and the terms such as "hematopoietic stem cell transplantation," "bone marrow transplant," "mortality," "opportunistic infections," and "survival" associated with "severe combined immunodeficiency" were sought based on the MeSH terms. The language of the articles was "English," and only articles published from 2000 onwards were selected. Twenty-three articles fulfilled the inclusion criteria for review and data extraction. The data collected corroborates that early HSCT, but above all, HSCT in patients without active infections, is related to better overall survival. The universal implementation of newborn screening for SCID will be a fundamental pillar for enabling most transplants to be carried out in this "ideal scenario" at an early age and free from infection. HSCT with an HLA-identical sibling donor is also associated with better survival rates, but this is the least common scenario. For this reason, transplantation with matched unrelated donors (MUD) and mismatched related donors (mMRD/Haploidentical) appear as alternatives. The results obtained with MUD are improving and show survival rates similar to those of MSD, as well as they do not require manipulation of the graft with expensive technologies. However, they still have high rates of complications after HSCT. Transplants with mMRD/Haplo are performed just in a few large centers because of the high costs of the technology to perform CD3/CD19 depletion and TCRαβ/CD19 depletion or CD34 + selection techniques in vitro. The new possibility of in vivo T cell depletion using post-transplant cyclophosphamide could also be a viable alternative for performing mMRD transplants in centers that do not have this technology, especially in developing countries.

immunology,allergy

A Framework for Interactive Problem Solving Based on Interactive Query Revision

[Advances in Newborn Screening and Immune System Reconstitution of Severe Combined Immunodeficiency].

Family members' informal roles in end-of-life decision making in adult intensive care units.

Reducing Mortality and Morbidity in Children with Severe Combined Immunodeficiency in Switzerland: the Role of Newborn Screening

A Modular Genetic Approach to Newborn Screening from Spinal Muscular Atrophy to Sickle Cell Disease—Results from Six Years of Genetic Newborn Screening

[Inapparent forms of edema in infectious hepatitis].

Clinical and economic aspects of newborn screening for severe combined immunodeficiency: DEPISTREC study results

AT1 receptors mediate chronic central nervous system AII hypertension in rats fed high sodium chloride diet from weaning.

Severe combined immunodeficiency with a homozygous c.464T>C (p.Leu155Pro) mutation in the RAG2 gene in a country without neonatal screening: Report of two clinical cases

Severe combined immunodeficiency diagnosis and genetic defects

A Multicenter Prospective Study of Next-Generation Sequencing-Based Newborn Screening for Monogenic Genetic Diseases in China

Application of a Next-Generation Sequencing (NGS) Panel in Newborn Screening Efficiently Identifies Inborn Disorders of Neonates

Importance of the route of administration of ccl 4 in the protective effect of promethazine.

A novel pathogenic mutation on Interleukin-7 receptor leading to severe combined immunodeficiency identified with newborn screening and whole exome sequencing

Paving the way in implementation of SCID newborn screening in developing nations: feasibility study and strategies to move forward in Malaysia

Target Diseases for Neonatal Screening in Germany

A report of two cases of severe X-linked combined immunodeficiency in one family and literature review

Absence of short-loop autoregulation of prolactin during late pregnancy in the rat

Mass is more: The conceiving of (un)countability and its encoding into language in 5-year-old-children

A Large Cohort of RAG1/2-Deficient SCID Patients—Clinical, Immunological, and Prognostic Analysis

Survival After Hematopoietic Stem Cell Transplantation in Severe Combined Immunodeficiency (SCID): A Worldwide Review of the Prognostic Variables